Valuation: Telix Pharmaceuticals Limited

Market Cap 5.49B 3.93B 3.37B 3.15B 2.88B 5.43B 376B 37.26B 14.49B 189B 14.75B 14.43B 625B P/E 2026 *
246x
P/E 2027 * 167x
Enterprise Value 5.92B 4.23B 3.63B 3.4B 3.1B 5.86B 406B 40.18B 15.62B 204B 15.9B 15.56B 674B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 3.8x
Free-Float
83.35%
Yield 2026 *
-
Yield 2027 * -
1 day+3.46%
1 week-3.41%
Current month+13.72%
1 month+6.53%
3 months+21.32%
6 months+68.16%
Current year+44.29%
1 week 15.2
Extreme 15.195
18.13
1 month 13.95
Extreme 13.95
18.13
Current year 8.26
Extreme 8.26
18.13
1 year 8.26
Extreme 8.26
19.07
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap.
06/11/25 Fiscal year

Founder

100,708 0.0298%
17/06/25 Free

Founder

2,595 0.0008%
17/06/25 Free

Founder

166,483 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%-3.41%-11.84%+65.07% 3.8B
-0.74%+4.48%+3.74%+22.46% 51.61B
+1.00%-0.14%+493.51%+565.32% 44.89B
+0.18%+7.90%+38.45%+20.79% 42.77B
-0.68%+2.46%+20.35%+86.76% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.20%+3.67%+32.61%+144.85% 17.33B
-0.52%+1.74% - - 16.63B
+0.58%+4.00%+7.17%+30.59% 14.76B
+1.24%+3.87%+81.43%+49.90% 14.09B
Average +0.41%+3.68%+75.85%+115.88% 28.03B
Weighted average by Cap. +0.02%+4.97%+103.09%+139.79%

Financials

2026 *2027 *
Net sales 1.37B 980M 840M 786M 719M 1.36B 93.88B 9.3B 3.62B 47.14B 3.68B 3.6B 156B 1.58B 1.13B 967M 904M 827M 1.56B 108B 10.7B 4.16B 54.23B 4.23B 4.14B 179B
Net income 25.05M 17.92M 15.36M 14.37M 13.14M 24.79M 1.72B 170M 66.11M 862M 67.29M 65.83M 2.85B 19.91M 14.24M 12.21M 11.42M 10.44M 19.7M 1.36B 135M 52.55M 685M 53.48M 52.32M 2.27B
Net Debt 429M 307M 263M 246M 225M 425M 29.39B 2.91B 1.13B 14.76B 1.15B 1.13B 48.83B 498M 356M 305M 285M 261M 492M 34.09B 3.38B 1.31B 17.12B 1.34B 1.31B 56.63B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
24/08/26 A$16.16 +3.46% 1,683,785
21/08/26 A$15.62 -10.13% 4,587,381
20/08/26 A$17.38 +3.21% 5,205,523
19/08/26 A$16.84 +0.48% 974,002
18/08/26 A$16.76 +1.88% 2,024,589
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
16.16AUD
Average target price
23.44AUD
Spread / Average Target
+45.03%

Quarterly revenue - Rate of surprise